Myriad Genetics Eyes GeneSight

Myriad Genetics Inc. (NASDAQ: MYGN), which specializes in molecular diagnostics and personalized medicine, started off August with the acquisition of privately-held Assurex Health Inc., an informatics-based, personalized medicine company that specializes in pharmacogenomics, a study of the genetic factors that influence an individual’s response to drug treatments, for behavioral health and chronic pain conditions. Assurex was sold for an upfront payment of $225 million, and is also eligible to receive up to $185 million in additional performance-based milestones. The acquisition gives Myriad access to GeneSight®, one of the fasting growing diagnostic tests in a multi-billion dollar market.... Read More »